Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorundrostat Open-Label Extension Study in Hypertension
NCT05968430Phase 3Active, not recruiting
- Sponsor
- Mineralys Therapeutics
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of lorundrostat in hypertension (HTN), sponsored by Mineralys Therapeutics. Started Jul 2023; status: active, not recruiting.
02
Drugs
lorundrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05968430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05968430.